Portopulmonary Hypertension

Yu Kuang Lai; Paul Y Kwo

doi:10.1016/j.cld.2022.08.002

Portopulmonary Hypertension

Clin Liver Dis. 2023 Feb;27(1):71-84. doi: 10.1016/j.cld.2022.08.002. Epub 2022 Oct 18.

Authors

Yu Kuang Lai¹, Paul Y Kwo²

Affiliations

¹ Pulmonary, Allergy and Critical Care, Department of Medicine, Stanford University, 300 Pasteur Drive, Room H3143, Palo Alto, CA 94304, USA.
² Stanford University School of Medicine, 430 Broadway, Pavilion C, 3rd Floor, Redwood City, CA 94063, USA. Electronic address: pkwo@stanford.edu.

PMID: 36400468
DOI: 10.1016/j.cld.2022.08.002

Abstract

PoPH is a well-recognized complication of portal hypertension with or without cirrhosis and is classified as a subset of PAH. Identification of PoPH is crucial as it has a major impact on prognosis and liver transplant candidacy. Echocardiogram is the initial screening tool of choice and the patient should proceed to RHC for confirmation. PAH-directed therapy is the treatment of choice, allowing the patient to achieve a hemodynamic threshold to undergo a liver transplant safely.

Keywords: Liver transplant; Portopulmonary hypertension; Pulmonary hypertension.

Publication types

Review

MeSH terms

Humans
Hypertension, Portal* / complications
Hypertension, Portal* / diagnosis
Hypertension, Pulmonary* / diagnosis
Hypertension, Pulmonary* / etiology
Hypertension, Pulmonary* / therapy
Liver Transplantation* / adverse effects
Prognosis